门静脉化疗配合肝切除治疗原发性肝癌临床研究

Clinical study of treatment of primary hepatic carcinoma by hepatectomy combined with portal vein chemotherapy

目的：探讨门静脉化疗配合肝切除治疗原发性肝癌的治疗效果及临床意义。方法：2001年1月-2006年1月收治76例原发性肝癌行根治性切除，其中，术后联合门静脉化疗（治疗组）38例，单纯根治性切除38例（对照组），全部患者随访2年以上。将两组患者术中情况、术后并发症、复发率、生存率进行对比研究。结果：两组患者术中情况、术后并发症情况无显著差异，治疗组与对照组之间的术后复发率与生存率均有明显差异。结论：肝癌根治性切除后，联合门静脉化疗明显降低术后复发率，提高术后生存率。

Objective：To explore the therapeutic effect and clinical significance of hepatectomy combined with portal vein chemotherapy in treatment of primary hepatic carcinoma. Methods： From January, 2001 to January, 2006, 76 cases of liver primary carcinoma underwent radical tumor resectior, After operation, portal vein chemotherapy was performed in the treated group （38 cases）, while the other 38 cases in the control group didn＇t undergone chemotherapy. All cases were followed up for over 2 years. The intraoperative condition, postoperative complications, recurrence rate, survival rate were compared between two groups. Results： There was no significant difference between the two groups in intraoperative conditions and postoperative complications. However, in the treated group recurrence rate were significantly lower and survival rate were significantly higher than those in the control group. Conclusion： Hepatectomy combined with portal vein chemotherapy can obviously reduce recurrence rate and raise the survival rate.